GlassScriptPhysician profile
Nicholas C Sorrel
NPI 1700131950
$5,277.82
in general payments reported to CMS, 2019-2025
23 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 86% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $92.26 · 2021: $262 · 2022: $1,806 · 2023: $771 · 2024: $516 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.51 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,375.60 | 2022-2025 | Inspire |
| Aerin Medical INC. | $1,054.42 | 2019-2025 | |
| Acclarent, INC | $791.38 | 2019-2023 | Trudi Nav Cable, Spine & Trauma 3d Navigation, Acclarent Aera |
| Medtronic, INC. | $585.34 | 2021-2024 | Stealthstation S8 Platform, N/A |
| Genzyme Corporation | $333.83 | 2022-2025 | |
| Optinose US, INC. | $255.67 | 2019-2025 | |
| Stryker Corporation | $200.86 | 2019-2025 | Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $135.20 | 2021-2025 | Dupixent |
| Amgen INC. | $111.32 | 2024 | Tepezza |
| Glaxosmithkline, LLC. | $109.04 | 2022-2025 | Nucala |
| Kaleo, INC. | $56.14 | 2019-2022 | |
| Phadia US INC. | $48.51 | 2023 | Immunocap |
| Integra Lifesciences Corporation | $44.19 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Davol INC. | $25.01 | 2023 | Arista Ah Flexitip |
| Ethicon US, LLC | $23.80 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $22.54 | 2021 | |
| Merck Sharp & Dohme LLC | $18.20 | 2021 | |
| Hikma Pharmaceuticals USA | $15.89 | 2022 | |
| Aytu Biopharma, INC. | $15.71 | 2025 | |
| Itamar Medical INC | $15.11 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $14.07 | 2024 | Lumryz |
| Alk-Abello, INC | $13.37 | 2020 | |
| Cook Medical LLC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Sorrel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.